RNAse monoclonal antibody-LL2-I-131-conjugate

Drug Profile

RNAse monoclonal antibody-LL2-I-131-conjugate

Alternative Names: Monoclonal antibody LL2-I-131- RNAse conjugate; RNAse conjugate - Immunomedics; RNAse-LymphoCide conjugate - Immunomedics

Latest Information Update: 12 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomedics; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 31 Jul 2002 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (unspecified route)
  • 31 Jul 2002 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 09 Mar 2000 Preclinical development for Non-Hodgkin's lymphoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top